Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stada Expands In Ukraine With Biopharma Deal

Acquisition Of Prescription And Consumer Units To Close By Year End

Executive Summary

Stada has struck a deal to acquire the prescription and consumer health businesses of Ukraine’s Biopharma, including local manufacturing operations and around 300 new staff. Biopharma will retain its blood plasma-based business.

You may also be interested in...



Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights

Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.

Stada Grows In Russia And CIS With Takeda Deal

Stada will pay $660m for a basket of 20 brands from Takeda to expand its consumer health portfolio in Russia and a number of strategically important CIS markets.

Alvotech And Stada Make Biosimilars Pact

Alvotech and Stada have struck a deal that will give Stada exclusive rights to sell seven Alvotech biosimilars “in all key European markets” as well as certain other territories.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149405

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel